Immatics Biotechnologies GmbH - Strategic SWOT Analysis Review

Immatics Biotechnologies GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy –  summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights


Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel technology, XPRESIDENT discovery platform. The company has active programs in several tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer. Its major drug candidates include IMA101, IMA201, IMA202, IMA203, and IMA301 which are focused on the development of three ACT approaches ACTolog, ACTengine, and ACTallo to treat cancer. The company has collaborations with Roche, UTHealth and MorphoSys for the advancement of drug candidates. Immatics is headquartered in Tuebingen, Germany.

Immatics Biotechnologies GmbH Key Recent Developments

Feb 21,2020: GSK and Immatics partner on cell therapies for cancer
Nov 12,2019: Immatics Implements Genedata Biologics into proprietary T-cell receptor discovery and engineering XCEPTOR platform
Jul 08,2019: Immatics appoints Harpreet Singh as chief executive officer
May 13,2019: Immatics to present at CIMT Annual Meeting 2019 (May 21-23) in Mainz, Germany
Feb 27,2019: Immatics and Roche to trial combination therapy for solid tumours

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with  detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.
 


Section 1 - About the Company
Immatics Biotechnologies GmbH - Key Facts
Immatics Biotechnologies GmbH - Key Employees
Immatics Biotechnologies GmbH - Key Employee Biographies
Immatics Biotechnologies GmbH - Major Products and Services
Immatics Biotechnologies GmbH - History
Immatics Biotechnologies GmbH - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Immatics Biotechnologies GmbH - Business Description
Immatics Biotechnologies GmbH - SWOT Analysis
SWOT Analysis - Overview
Immatics Biotechnologies GmbH - Strengths
Immatics Biotechnologies GmbH - Weaknesses
Immatics Biotechnologies GmbH - Opportunities
Immatics Biotechnologies GmbH - Threats
Immatics Biotechnologies GmbH - Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Immatics Biotechnologies GmbH, Recent Deals Summary
Section 4 – Company’s Recent Developments
Feb 21, 2020: GSK and Immatics partner on cell therapies for cancer
Nov 12, 2019: Immatics Implements Genedata Biologics into proprietary T-cell receptor discovery and engineering XCEPTOR platform
Jul 08, 2019: Immatics appoints Harpreet Singh as chief executive officer
May 13, 2019: Immatics to present at CIMT Annual Meeting 2019 (May 21-23) in Mainz, Germany
Feb 27, 2019: Immatics and Roche to trial combination therapy for solid tumours
Jan 11, 2019: Immatics at the 18th PepTalk in San Diego, CA
Jan 03, 2019: US Patent Office Grants the 100th Patent to Immatics Underpinning the Company’s Leading Role in the Field of Innovative Immunotherapies
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
 


List Of Tables


Immatics Biotechnologies GmbH, Key Facts
Immatics Biotechnologies GmbH, Key Employees
Immatics Biotechnologies GmbH, Key Employee Biographies
Immatics Biotechnologies GmbH, Major Products and Services
Immatics Biotechnologies GmbH, History
Immatics Biotechnologies GmbH, Other Locations
Immatics Biotechnologies GmbH, Subsidiaries
Immatics Biotechnologies GmbH, Key Competitors
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Immatics Biotechnologies GmbH, Recent Deals Summary
 


List Of Figures


Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
 


Immatics Biotechnologies GmbH - Strategic SWOT Analysis Review

Immatics Biotechnologies GmbH - Strategic SWOT Analysis Review

USD 125 View Report

Immatics Biotechnologies GmbH - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Immatics Biotechnologies GmbH - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Immatics Biotechnologies GmbH Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description,

USD 350 View Report

Immatics Biotechnologies GmbH - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Immatics Biotechnologies GmbH - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Immatics Biotechnologies GmbH Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description,

USD 350 View Report

Immatics Biotechnologies GmbH - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel

USD 250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available